论文部分内容阅读
自七十年代初期阿霉素(DX)进入临床化疗以来,已治疗二百多万例。但由于产生较严重的毒副反应故影响其临床广泛应用。此外,阿霉素对结肠直肠癌、胰腺癌、肾癌疗效均甚低,因而对其衍生物已投入大量研究,其中表阿霉素(Epirubicin,4’-epidoxorubicin)、4-去甲氧柔红霉素(Idarubicin,4-demethoxydaunorubic—in,4-DMDR)和4’-去氧阿霉素(Esorubicin,4’-deoxydoxorubicin)是近年来发展的一组抗肿瘤活性强、毒性低的蒽环类化合物,已分别进
More than two million have been treated since the advent of doxorubicin (DX) in clinical chemotherapy in the early 1970s. However, due to produce more serious adverse reactions affect its clinical application. In addition, doxorubicin on colorectal cancer, pancreatic cancer, renal cancer are very low efficacy, and thus its derivatives have been devoted to a large number of studies, including epirubicin (Epirubicin, 4’-epidoxorubicin), 4- Idarubicin (4-demethoxydaunorubic-in, 4-DMDR) and 4’-deoxydoxorubicin are a group of anti-tumor activity and low toxicity Class compounds, have been entered separately